Profile data is unavailable for this security.
About the company
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The Company’s lead product candidate is ANEB-001, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat ACI. ANEB-001 is an orally bioavailable, rapidly absorbed treatment that it anticipates is rapidly reverse the symptoms of ACI and reduce the time to recovery. The signs and symptoms of ACI range from profound sedation to anxiety and panic to psychosis with hallucinations. CB1 receptors are concentrated in the brain and central nervous system, while CB2 receptors are found in peripheral organs and are associated with the immune system.
- Revenue in USD (TTM)0.00
- Net income in USD-9.35m
- Incorporated2020
- Employees2.00
- LocationAnebulo Pharmaceuticals IncJfl Capital Management1017 Rr 620 S, Suite 107LAKEWAY 78734United StatesUSA
- Phone+1 (512) 598-0931
- Websitehttps://www.anebulo.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enzo Biochem Inc | 32.80m | -23.31m | 53.79m | 179.00 | -- | 0.749 | -- | 1.64 | -0.4699 | 0.6708 | 0.6586 | 1.40 | 0.3738 | 1.61 | 4.10 | 183,257.00 | -26.56 | -12.21 | -39.50 | -15.79 | 42.17 | 37.09 | -71.07 | -18.76 | 2.89 | -- | 0.0476 | -- | -4.85 | -21.01 | -23.02 | -- | 7.89 | -- |
| Cidara Therapeutics Inc | 46.38m | -36.47m | 54.38m | 69.00 | -- | -- | -- | 1.17 | -8.07 | -8.07 | 10.26 | -3.90 | 0.6899 | -- | 2.80 | 672,144.90 | -54.24 | -65.23 | -218.59 | -154.37 | 76.93 | -- | -78.63 | -100.61 | 0.6047 | -- | -- | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| Rockwell Medical Inc | 86.62m | -8.42m | 55.02m | 237.00 | -- | -- | -- | 0.6352 | -0.3584 | -0.3584 | 3.33 | -- | -- | -- | -- | 365,485.20 | -- | -46.29 | -- | -65.38 | 10.59 | 4.66 | -9.72 | -36.51 | -- | -3.41 | -- | -- | 14.84 | 5.69 | 54.82 | -- | 76.21 | -- |
| Calcimedica Inc | 0.00 | -14.94m | 55.47m | 14.00 | -- | 3.21 | -- | -- | -2.64 | -2.64 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -48.34 | -63.99 | -66.59 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
| China Health Industries Holdings, Inc. | 117.28k | -1.51m | 55.71m | 32.00 | -- | -- | -- | 475.01 | -0.023 | -0.023 | 0.0018 | -0.0349 | 0.0044 | 0.5692 | 25.25 | 3,665.00 | -5.72 | 3.04 | -7.60 | 3.66 | -2.37 | 69.55 | -1,287.13 | 28.61 | 0.0377 | -- | 1.68 | -- | 41,225.93 | -55.72 | -15.49 | -- | -- | -- |
| Immix Biopharma Inc | 0.00 | -18.21m | 56.00m | 14.00 | -- | 2.00 | -- | -- | -0.9263 | -0.9263 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -77.50 | -- | -90.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
| Protara Therapeutics Inc | 0.00 | -42.47m | 56.83m | 26.00 | -- | 0.5403 | -- | -- | -3.74 | -3.74 | 0.00 | 5.11 | 0.00 | -- | -- | 0.00 | -48.67 | -37.02 | -52.23 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -9.35m | 57.57m | 2.00 | -- | 11.55 | -- | -- | -0.3633 | -0.3633 | 0.00 | 0.1922 | 0.00 | -- | -- | 0.00 | -91.51 | -- | -104.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
| Reneo Pharmaceuticals Inc | 0.00 | -70.71m | 57.82m | 8.00 | -- | 0.7117 | -- | -- | -2.17 | -2.17 | 0.00 | 2.43 | 0.00 | -- | -- | 0.00 | -77.06 | -- | -83.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Kronos Bio Inc | 7.59m | -116.39m | 58.29m | 61.00 | -- | 0.4256 | -- | 7.68 | -2.00 | -2.00 | 0.1301 | 2.28 | 0.0322 | -- | -- | 122,371.00 | -49.32 | -35.47 | -54.43 | -37.14 | -- | -- | -1,534.11 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 59.28m | 217.00 | -- | 0.4376 | -- | 18.65 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| Turnstone Biologics Corp | 0.00 | -74.92m | 59.67m | 82.00 | -- | 0.7458 | -- | -- | -3.53 | -3.53 | 0.00 | 3.46 | 0.00 | -- | -- | 0.00 | -80.25 | -- | -94.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
| AN2 Therapeutics Inc | 0.00 | -66.03m | 59.96m | 41.00 | -- | 0.5419 | -- | -- | -2.59 | -2.59 | 0.00 | 3.71 | 0.00 | -- | -- | 0.00 | -62.19 | -- | -68.38 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Mural Oncology PLC | 0.00 | -191.90m | 60.76m | 117.00 | -- | 0.2586 | -- | -- | -11.49 | -11.49 | 0.00 | 13.88 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
| VolitionRX Ltd | 797.03k | -34.91m | 61.50m | 110.00 | -- | -- | -- | 77.16 | -0.4603 | -0.4603 | 0.0104 | -0.1901 | 0.0425 | -- | 6.32 | 7,245.73 | -188.25 | -111.92 | -- | -196.20 | -- | -- | -4,425.95 | -10,793.31 | -- | -173.85 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
Data as of May 24 2024. Currency figures normalised to Anebulo Pharmaceuticals Inc's reporting currency: US Dollar USD
28.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| 22NW LPas of 31 Mar 2024 | 5.37m | 20.69% |
| LVW Advisors LLCas of 31 Mar 2024 | 642.04k | 2.48% |
| Nantahala Capital Management LLCas of 31 Mar 2024 | 511.07k | 1.97% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 399.22k | 1.54% |
| Ikarian Capital LLCas of 31 Mar 2024 | 157.86k | 0.61% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 153.47k | 0.59% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 25.25k | 0.10% |
| Geode Capital Management LLCas of 31 Mar 2024 | 22.78k | 0.09% |
| Boothbay Fund Management LLCas of 31 Mar 2024 | 18.98k | 0.07% |
| Tower Research Capital LLCas of 31 Mar 2024 | 5.14k | 0.02% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
